Cue Biopharma (CUE)
(Delayed Data from NSDQ)
$1.65 USD
-0.06 (-3.51%)
Updated Nov 6, 2024 04:00 PM ET
Pre-Market: $1.65 0.00 (0.00%) 9:26 AM ET
2-Buy of 5 2
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.65 USD
-0.06 (-3.51%)
Updated Nov 6, 2024 04:00 PM ET
Pre-Market: $1.65 0.00 (0.00%) 9:26 AM ET
2-Buy of 5 2
F Value C Growth D Momentum F VGM
Zacks News
Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 6.4% Jump Turn into More Strength?
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -50% and 2%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
ChromaDex (CDXC) delivered earnings and revenue surprises of 27.27% and 3.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
YmAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -19.72% and 7.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Bellus Health (BLU) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Bellus (BLU) delivered earnings and revenue surprises of 35.71% and 60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cue Biopharma, Inc. (CUE) Stock Jumps 6.5%: Will It Continue to Soar?
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Analysts Estimate Cue Biopharma, Inc. (CUE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Cue Biopharma, Inc. (CUE) Q2 Earnings Expected to Decline
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 27.7% Jump Turn into More Strength?
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Do Options Traders Know Something About Cue Biopharma (CUE) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Cue Biopharma (CUE) stock based on the movements in the options market lately.
Cue Biopharma (CUE) Catches Eye: Stock Jumps 5.2%
by Zacks Equity Research
Cue Biopharma (CUE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Cue Biopharma, Inc. (CUE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cue Biopharma, Inc. (CUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cue Biopharma, Inc. (CUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: ThermoGenesis, 21Vianet, Livongo Health, Cue Biopharma and Sharps Compliance
by Zacks Equity Research
Zacks.com featured highlights include: ThermoGenesis, 21Vianet, Livongo Health, Cue Biopharma and Sharps Compliance
The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
5 Stocks With Recent Price Strength to Tap Market Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
5 Top Small-Cap Stocks Braving Coronavirus Bloodbath
by Nalak Das
A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.
Should You Buy Cue Biopharma (CUE) Ahead of Earnings
by Zacks Equity Research
Cue Biopharma (CUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cue Biopharma, Inc. (CUE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Farmers National, Independent Bank, First Financial Bankshares, HarborOne and Cue Biopharma
by Zacks Equity Research
Zacks.com featured highlights include: Farmers National, Independent Bank, First Financial Bankshares, HarborOne and Cue Biopharma
5 Stocks to Make the Most of New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Zacks.com featured highlights include: Independent Bank, HarborOne, Horizon Technology Finance and Cue Biopharma
by Zacks Equity Research
Zacks.com featured highlights include: Independent Bank, HarborOne, Horizon Technology Finance and Cue Biopharma
4 Stocks in Focus as New Analysts Show Interest
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.